UCLA researchers use F-18 FDDNP to visualize beta-amyloid load in vivo
CONTEXT: Neurotoxic beta-amyloid accumulates in regions of the brain affected by advanced Alzheimer's disease. It is a suspected contributor to the development of the condition.
RESULTS: Dr. Jorge Barrio and researchers from the University of California, Los Angeles demonstrated that F-18 FDDNP microPET can visualize b-amyloid load in vivo in the brains of transgenic mice. Dynamic scans with the agent were performed on three experimental and two control animals. FDDNP uptake was elevated in the cerebral cortex, most prominently in the frontal lobe and hippocampal regions of the experimental transgenic mice (p = 0.001). Only background cortical binding was seen in control subjects. Results were consistent with previous in vitro results with b-amyloid neurofibrils and brain specimens of Alzheimer's disease patients. They were presented at the 2005 Academy of Molecular Imaging meeting.
IMPLICATIONS: The ability to quantify beta-amyloid plaque load could identify healthy adults who are suspicious for the future development of AD and could play a role in monitoring the effect of anti-amyloid therapies.
Can Abbreviated MRI Have an Impact in Rectal Cancer Staging?
April 4th 2025Abbreviated MRI demonstrated a 95.3 percent specificity for rectal cancer and provided strong agreement with the full MRI protocol for T staging and detection of extramural venous invasion, according to newly published research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
